MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acr.25396

Медицинская библиотека · Arthritis care & research · 2024

Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.

Linde Louise, Georgiadis Stylianos, Ørnbjerg Lykke M, Rasmussen Simon H, Michelsen Brigitte, Askling Johan, Di Giuseppe Daniela, Wallman Johan K, Závada Jakub, Pavelka Karel, Bernardes Miguel, Matos Carolina O, Glintborg Bente, Loft Anne Gitte, Nordström Dan, Kuusalo Laura, Möller Burkhard, Nissen Michael J, Codreanu Catalin, Mogosan Corina, Gudbjornsson Bjorn, Love Thorvardur Jon, Akleylek Cansu, Iannone Florenzo, Kvien Tore K, Rotar Ziga, Castrejon Isabel, Macfarlane Gary J, Hetland Merete L, Østergaard Mikkel

СтатьяСравнительное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Because 66/68 joint counts are not always performed in routine care, we aimed to determine which of the modified 28-joint disease activity index for psoriatic arthritis (DAPSA28) or 28-joint disease activity score with C-reactive protein (DAS28-CRP) should be preferred for monitoring disease activity in psoriatic arthritis (PsA) when the original DAPSA (66/68 joints) is not available.

METHODS

Prospectively collected real-world data of European bionaive patients with PsA initiating a first tumor necrosis factor inhibitor were pooled. Remission and response status were evaluated at 6 months by remission (DAPSA ≤ 4, DAPSA28 ≤ 4, and DAS28-CRP < 2.6), response (75% improvement for DAPSA and DAPSA28), and combined EULAR good/moderate responses for DAS28-CRP. Logistic regression analyses on multiple imputed data were used to identify baseline predictors.

RESULTS

Remission and response cohorts included 3,159 and 1,866 patients, respectively. The 6-month proportions achieving remission/response were DAPSA (27%/44%), DAPSA28 (28%/44%), and DAS28-CRP (59%/80%). Of 14 possible baseline predictors, 11 predicted both DAPSA and DAPSA28 remission (8 of which also predicted their response, indicated by "*"): longer disease duration*, male sex*, and higher CRP* were positive, whereas older age*, higher body mass index*, patient fatigue*, and global, physician global, health assessment questionnaire score*, and tender and swollen* joint counts were negative predictors. Eight and five of these predicted DAS28-CRP remission and response, respectively.

CONCLUSION

In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.

Для цитирования: Linde Louise, Georgiadis Stylianos, Ørnbjerg Lykke M, Rasmussen Simon H, Michelsen Brigitte, Askling Johan, Di Giuseppe Daniela, Wallman Johan K, Závada Jakub, Pavelka Karel, Bernardes Miguel, Matos Carolina O, Glintborg Bente, Loft Anne Gitte, Nordström Dan, Kuusalo Laura, Möller Burkhard, Nissen Michael J, Codreanu Catalin, Mogosan Corina, Gudbjornsson Bjorn, Love Thorvardur Jon, Akleylek Cansu, Iannone Florenzo, Kvien Tore K, Rotar Ziga, Castrejon Isabel, Macfarlane Gary J, Hetland Merete L, Østergaard Mikkel. Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.. Arthritis care & research. 2024. DOI: 10.1002/acr.25396.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.